Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation

被引:36
作者
Wei, Changran [1 ]
Li, Xiangqi [1 ,2 ]
机构
[1] Shandong Univ Tradit Chinese Med, Jinan, Shandong, Peoples R China
[2] Shandong First Med Univ, Dept Breast Surg, Affiliated Hosp 2, 706 TaiShan Rd, Tai An 271000, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; YAP; Verteporfin; Cell proliferation; Apoptosis; TISSUE GROWTH-FACTOR; UVEAL MELANOMA; TUMOR-CELLS; YAP; HIPPO; EXPRESSION; KINASE;
D O I
10.1186/s12885-020-07555-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundBreast cancer (BC) can be divided into five subtypes: Lumina1A, Lumina1B, HER-2 overexpression, Basal-like and Normal breast-like subtype, based on the differently expressed genes in breast cancer tissue. The Hippo signaling pathway plays an indispensable role in BC. The YAP gene is a terminal effector of Hippo pathway, and hyperactivation of YAP mediates tumorigenesis. As an inhibitor of YAP, non-photoactivated verteporfin (VP) can inhibit YAP-mediated tumor proliferation and angiogenesis by eliminating its interaction with TEAD. This study aimed to determine the effect and molecular mechanisms of VP-mediated inhibition of YAP in different subtypes of BC.MethodsLuminal A, Luminal B and Basal-like BC cells were cultivated in vitro to study effects of VP on proliferation and apoptosis of these three molecular BC subtypes.ResultsOur experimental results showed that VP inhibited cell proliferation, YAP-TEAD interaction and expression of its downstream targets. VP also induced tumor cell apoptosis, and promoted the cleavage of Caspase-9 and PARP in the cells of various molecular subtypes of BC.ConclusionThese findings provide a basis for the use of VP as a potential anti-tumor therapeutic for BC by targeting the Hippo pathway effector YAP.
引用
收藏
页数:8
相关论文
共 38 条
[1]   Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].
Bray, Freddie ;
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Siegel, Rebecca L. ;
Torre, Lindsey A. ;
Jemal, Ahmedin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2018, 68 (06) :394-424
[2]   A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis [J].
Chen, Qian ;
Zhang, Nailing ;
Gray, Ryan S. ;
Li, Huili ;
Ewald, Andrew J. ;
Zahnow, Cynthia A. ;
Pan, Duojia .
GENES & DEVELOPMENT, 2014, 28 (05) :432-437
[3]  
Chien W, 2013, INT J ONCOL, V38, P1741
[4]   PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials [J].
Dey, Nandini ;
De, Pradip ;
Leyland-Jones, Brian .
PHARMACOLOGY & THERAPEUTICS, 2017, 175 :91-106
[5]   Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM) [J].
Duffy, M. J. ;
Harbeck, N. ;
Nap, M. ;
Molina, R. ;
Nicolini, A. ;
Senkus, E. ;
Cardoso, F. .
EUROPEAN JOURNAL OF CANCER, 2017, 75 :284-298
[6]   The Hippo pathway in organ development, homeostasis, and regeneration [J].
Fu, Vivian ;
Plouffe, Steven W. ;
Guan, Kun-Liang .
CURRENT OPINION IN CELL BIOLOGY, 2017, 49 :99-107
[7]   Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway [J].
Gibault, Floriane ;
Bailly, Fabrice ;
Corvaisier, Matthieu ;
Coevoet, Mathilde ;
Huet, Guillemette ;
Melnyk, Patricia ;
Cotelle, Philippe .
CHEMMEDCHEM, 2017, 12 (12) :954-961
[8]   Non-Photoinduced Biological Properties of Verteporfin [J].
Gibault, Floriane ;
Corvaisier, Matthieu ;
Bailly, Fabrice ;
Huet, Guillemette ;
Melnyk, Patricia ;
Cotelle, Philippe .
CURRENT MEDICINAL CHEMISTRY, 2016, 23 (11) :1171-1184
[9]   The global burden of women's cancers: a grand challenge in global health [J].
Ginsburg, Ophira ;
Bray, Freddie ;
Coleman, Michel P. ;
Vanderpuye, Verna ;
Eniu, Alexandru ;
Kotha, S. Rani ;
Sarker, Malabika ;
Tran Thanh Huong ;
Allemani, Claudia ;
Dvaladze, Allison ;
Gralow, Julie ;
Yeates, Karen ;
Taylor, Carolyn ;
Oomman, Nandini ;
Krishnan, Suneeta ;
Sullivan, Richard ;
Kombe, Dominista ;
Blas, Magaly M. ;
Parham, Groesbeck ;
Kassami, Natasha ;
Conteh, Lesong .
LANCET, 2017, 389 (10071) :847-860
[10]   Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival [J].
Gjerdrum, Christine ;
Tiron, Crina ;
Hoiby, Torill ;
Stefansson, Ingunn ;
Haugen, Hallvard ;
Sandal, Tone ;
Collett, Karin ;
Li, Shan ;
McCormack, Emmet ;
Gjertsen, Bjorn Tore ;
Micklem, David R. ;
Akslen, Lars A. ;
Glackin, Carlotta ;
Lorens, James B. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (03) :1124-1129